Malignant pleural mesothelioma

1 paper

Cells1

Trial sponsors

Ferring Ventures
Company1 trialPhase 353 people
Morphotek
Company1 trialPhase 289 people
Eli Lilly and Company
Company1 trialPhase 220 people
CanBas
Company1 trialPhase 1/269 people
Sumitomo Pharma
Company1 trialPhase 1/228 people
Nurix Therapeutics
Company1 trialPhase 1345 people
Aduro Biotech
Company1 trialPhase 160 people
PrECOG
1 trialPhase 3214 people

Latest

1 in 12 months

Cellular OncologyJun 8

Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells

Experiments in human cellsCellular senescence